The Vietnam cardiac PoC testing devices market was valued at USD 10.55 Million in 2025 and is projected to reach USD 16.69 Million by 2034. It is expected to grow at a compound annual growth rate (CAGR) of 5.23% during the forecast period 2026-2034. The market expansion is driven by government healthcare reforms, infrastructure modernization, rising cardiovascular health awareness, and growing adoption of rapid diagnostic solutions integrated with advanced digital health and AI capabilities.

Study Assumption Years

• Base Year: 2025
• Historical Year/Period: 2020-2025
• Forecast Year/Period: 2026-2034

Vietnam Cardiac PoC Testing Devices Market Key Takeaways

• The market size was USD 10.55 Million in 2025, with a CAGR of 5.23% forecasted from 2026 to 2034.
• Cardiac markers test dominated the market with 63% share in 2025, attributed to its high specificity for myocardial injury detection.
• Hospitals led end users with a 55% market share in 2025 due to advanced infrastructure and high patient intake.
• The market shows moderate competitive intensity with multinational and regional manufacturers focusing on innovation and network expansion.
• Increasing government initiatives and digital transformation in healthcare are key market growth enablers.

Sample Request Link: https://www.imarcgroup.com/vietnam-cardiac-poc-testing-devices-market/requestsample

Market Growth Factors

The Vietnam cardiac PoC testing devices market growth is primarily driven by the rising prevalence of cardiovascular diseases, the leading cause of mortality in Vietnam. Changes in lifestyle due to urbanization, including sedentary habits, dietary changes, and increased stress, are escalating cardiac condition incidences. The growing burden of hypertension, diabetes, and obesity further contributes to cardiovascular risk, prompting healthcare providers to emphasize early detection and continuous monitoring. This shift is fueling investments in point-of-care testing infrastructure across hospitals and clinics, enabling faster and more accurate diagnostics for effective patient care.

Government healthcare investment and infrastructure development significantly bolster market growth. The Vietnamese government's comprehensive modernization programs, with significant funding for medical infrastructure, focus on enhancing local diagnostic capabilities and reducing reliance on foreign healthcare services. For example, in June 2024, the Ministry of Health sanctioned a program targeting early detection and management of non-communicable diseases through 2025. These initiatives support hospital capacity expansion, improve medical personnel ratios, and increase healthcare accessibility, facilitating procurement and integration of advanced cardiac testing technologies in both public and private sectors.

Technological advancements in diagnostic testing are revolutionizing cardiac biomarker assessment. The emergence of high-sensitivity assays allows early-stage cardiac event detection at lower biomarker concentrations, enabling prompt clinical interventions. Integration of artificial intelligence and machine learning enhances result interpretation, reduces diagnostic uncertainty, and supports clinical decision-making. Connected devices with cloud analytics enable real-time data sharing and monitoring, advancing telemedicine and population health management. These innovations make point-of-care cardiac testing more accurate, accessible, and cost-effective, accelerating market adoption.

Market Segmentation

Product Type

• Cardiac Markers Test: Dominates with 63% market share in 2025. This test is the cornerstone of point-of-care cardiac diagnostics, offering exceptional specificity and sensitivity in myocardial injury detection. It enables rapid acute coronary syndrome and myocardial infarction identification, supporting timely clinical interventions. The adoption of high-sensitivity troponin assays and multiplex biomarker platforms is enhancing early detection and comprehensive patient management.

Subtypes include:

• Cardiac Troponin (cTn) Test
• Myoglobin Test
• Creatine Kinase MB Isoenzyme (CK-MB) Test
• Combinational Test Kits
• Brain Natriuretic Peptide (BNP) Test Analyzers

End User

• Hospitals: Lead the market with a 55% share in 2025, driven by advanced infrastructure and high patient volumes necessitating rapid cardiac assessments. Emergency and intensive care units benefit from immediate biomarker results accelerating clinical decisions. Major hospital networks integrate advanced cardiac monitoring within digital health initiatives. Private hospitals in urban centers focus on cutting-edge diagnostics and comprehensive cardiac care, while government hospitals upgrade capabilities through public health programs.

Subcategories include Diagnostic Laboratories and Others.

Regional Insights

• Northern Vietnam: Including Hanoi and surroundings, drives demand due to cardiovascular disease prevalence and growing health awareness. Urban hospitals and diagnostic centers expand infrastructure with government support for early detection and preventive care, supported by rising disposable incomes.
• Central Vietnam: Growth fueled by hospital network expansion in cities like Da Nang and Hue, increasing cardiovascular risks, awareness, and investments in medical infrastructure and advanced diagnostics.
• Southern Vietnam: Encompassing Ho Chi Minh City and Mekong Delta, strong demand due to urbanization, lifestyle risks, and health awareness. Advanced hospitals and private clinics adopt rapid, reliable diagnostics, aided by government programs and rising incomes.

Regional Market Summary

Northern Vietnam is a dominant region experiencing increasing demand for cardiac PoC devices due to higher cardiovascular disease prevalence and rising healthcare awareness. Government initiatives and urban infrastructure expansion are fueling the adoption of rapid, convenient diagnostics, driving growth across clinics and hospitals in this region.

Market Restraints

The Vietnam cardiac PoC testing devices market faces challenges including limited access to advanced diagnostic technology, which remains concentrated in large referral hospitals while district and commune-level facilities lack sophisticated equipment. There is also a nationwide shortage of skilled healthcare personnel trained in point-of-care testing, restricting optimal device utilization, especially in underserved areas. High upfront costs of advanced devices and ongoing expenses related to reagents and maintenance create affordability hurdles. Limited reimbursement policies further restrict access to these technologies for lower-income populations.

Competitive Landscape

The Vietnam cardiac PoC testing devices market exhibits moderate competitive intensity with established multinational diagnostic corporations alongside emerging regional manufacturers. Leading global players utilize technological expertise, diverse product portfolios, and distribution networks to serve major healthcare facilities. Competition is escalating with a focus on expanding product portfolios, enhancing diagnostics, and strengthening service capabilities. Strategic partnerships between international manufacturers and local distributors facilitate market penetration and access to advanced technologies. Emphasis on AI integration, device connectivity, and enhanced user interfaces drives differentiation amid continuing price competition.

Key Players

• FPT Corporation
• TR Group
• AstraZeneca Vietnam

Recent Developments & News

In September 2025, South Korea's TR Group, supported by FPT Corporation, contributed Spirokit, an AI-enabled smart device for pulmonary function testing, to Lam Dong General Hospital and Hue University of Medicine and Pharmacy. This initiative included a complimentary screening program for chronic obstructive pulmonary disease (COPD), benefiting over 700 residents. The program marks the first in a series of joint efforts between FPT, TR Group, and Vietnamese hospitals under a cooperation agreement fostering advanced diagnostic technology exchange.

In September 2024, over 1,000 individuals received complimentary cardiovascular and kidney health screenings at Bạch Mai Hospital during the 'CAREME – Love Yourself' initiative, jointly organized by the Vietnam Youth Doctors Association, Bạch Mai Hospital, and AstraZeneca Vietnam, highlighting collaborative efforts to promote preventive healthcare.

Report Coverage

• Base Year of Analysis: 2025
• Historical Period: 2020-2025
• Forecast Period: 2026-2034
• Units: Million USD
• Product Types Covered: Cardiac Markers Test (including Cardiac Troponin (cTn), Myoglobin, CK-MB, Combinational Kits, BNP Test Analyzers)
• End Users Covered: Hospitals, Diagnostic Laboratories, Others
• Regions Covered: Northern Vietnam, Central Vietnam, Southern Vietnam

Customization Note

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302